Patents by Inventor Rachel Meyers

Rachel Meyers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20020034807
    Abstract: The invention provides isolated nucleic acids molecules, designated 38692 or 21117 nucleic acid molecules, which encode novel dual specificity phosphatase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 38692 or 21117 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 38692 or 21117 gene has been introduced or disrupted. The invention still further provides isolated 38692 or 21117 proteins, fusion proteins, antigenic peptides and anti-38692 or 21117 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: March 23, 2001
    Publication date: March 21, 2002
    Inventor: Rachel A. Meyers
  • Publication number: 20020034783
    Abstract: The invention provides isolated nucleic acids molecules, designated Adhr-1 nucleic acid molecules, which encode a novel family of alcohol dehydrogenase (Adh) proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing Adhr-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an Adhr-1 gene has been introduced or disrupted. The invention still further provides isolated Adhr-1 proteins, fusion proteins, antigenic peptides, and anti-Adhr-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: April 18, 2001
    Publication date: March 21, 2002
    Inventors: Rachel Meyers, Laura A. Rudolph-Owen
  • Publication number: 20020034780
    Abstract: The invention relates to novel kinase nucleic acid sequences and proteins. Also provided are vectors, host cells, and recombinant methods for making and using the novel molecules.
    Type: Application
    Filed: March 6, 2001
    Publication date: March 21, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel Meyers, Rosana Kapeller-Libermann, Mark Williamson
  • Publication number: 20020031815
    Abstract: The invention provides isolated and novel nucleic acids molecules, designated beta-ketoacyl synthase nucleic acid molecules, which encode novel beta-ketoacyl synthase polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing beta-ketoacyl synthase nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a beta-ketoacyl synthase gene has been introduced or disrupted. The invention still further provides isolated beta-ketoacyl synthase proteins, fusion proteins, antigenic peptides and anti-beta-ketoacyl synthase antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: June 26, 2001
    Publication date: March 14, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel A. Meyers, Mark Williamson
  • Publication number: 20020025931
    Abstract: The invention provides isolated nucleic acids molecules, designated 3714, 16742, 23546, or 13887 nucleic acid molecules, which encode novel protein kinases. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 3714, 16742, 23546, or 13887 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 3714, 16742, 23546, or 13887 gene has been introduced or disrupted. The invention still further provides isolated 3714, 16742, 23546, or 13887 proteins, fusion proteins, antigenic peptides and anti-3714, -16742, -23546, or -13887 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: March 23, 2001
    Publication date: February 28, 2002
    Inventors: Rachel Meyers, John Joseph Hunter
  • Publication number: 20020019030
    Abstract: The invention provides isolated nucleic acids molecules, designated transferase nucleic acid molecules, which encode novel transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing transferase nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a transferase gene has been introduced or disrupted. The invention still further provides isolated transferase proteins, fusion proteins, antigenic peptides and anti-transferase antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: February 27, 2001
    Publication date: February 14, 2002
    Inventors: Rachel Meyers, Kyle J. MacBeth, Laura Rudolph-Owen
  • Publication number: 20020016449
    Abstract: The invention provides isolated nucleic acids molecules, designated 46743 or 27417 nucleic acid molecules, which encode novel acyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 46743 or 27417 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 46743 or 27417 gene has been introduced or disrupted. The invention still further provides isolated 46743 or 27417 proteins, fusion proteins, antigenic peptides and anti-46743 or anti-27417 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: March 26, 2001
    Publication date: February 7, 2002
    Inventors: Rachel A. Meyers, Kyle J. Macbeth, Mark Williamson, Laura A. Rudolph-Owen, Fong-Ying Tsai
  • Publication number: 20020009779
    Abstract: The invention provides isolated nucleic acids molecules, designated 50365 nucleic acid molecules, which encode novel hexokinase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 50365 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 50365 gene has been introduced or disrupted. The invention still further provides isolated 50365 proteins, fusion proteins, antigenic peptides and anti-50365 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: May 21, 2001
    Publication date: January 24, 2002
    Inventors: Rachel A. Meyers, Mark Williamson
  • Publication number: 20020009777
    Abstract: The invention provides isolated nucleic acids molecules, designated 25552 nucleic acid molecules, which encode novel ubiE methyltransferase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25552 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25552 gene has been introduced or disrupted. The invention still further provides isolated 25552 proteins, fusion proteins, antigenic peptides and anti-25552 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: March 23, 2001
    Publication date: January 24, 2002
    Inventors: Rachel A. Meyers, Mark Williamson
  • Publication number: 20020009804
    Abstract: The present invention relates to newly identified small G-proteins. The invention also relates to polynucleotides encoding the proteins. The invention further relates to methods using the polypeptides and polynucleotides as a target for diagnosis and treatment in G-protein-mediated or -related disorders. The invention further relates to drug-screening methods using the polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the polypeptides and polynucleotides. The invention further relates to procedures for producing the polypeptides and polynucleotides.
    Type: Application
    Filed: February 27, 2001
    Publication date: January 24, 2002
    Inventor: Rachel Meyers
  • Publication number: 20020010946
    Abstract: The present invention relates to newly identified human ADHs belonging to the superfamily of mammalian alcohol dehydrogenases. The invention also relates to polynucleotides encoding the ADHs. The invention further relates to methods using the ADH polypeptides and polynucleotides as a target for diagnosis and treatment in ADH-mediated or -related disorders. The invention further relates to drug-screening methods using the ADH polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the ADH polypeptides and polynucleotides. The invention further relates to procedures for producing the ADH polypeptides and polynucleotides.
    Type: Application
    Filed: February 28, 2001
    Publication date: January 24, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventor: Rachel Meyers
  • Publication number: 20020006653
    Abstract: The invention provides isolated nucleic acids molecules, designated 25692 nucleic acid molecules, which encode novel O-Methyltransferase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25692 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25692 gene has been introduced or disrupted. The invention still further provides isolated 25692 proteins, fusion proteins, antigenic peptides and anti-25692 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: April 27, 2001
    Publication date: January 17, 2002
    Inventors: Rachel A. Meyers, Mark Williamson
  • Publication number: 20020004236
    Abstract: The invention provides isolated nucleic acids molecules, designated 27960 nucleic acid molecules, which encode novel ubiquitin-conjugating enzyme family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27960 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27960 gene has been introduced or disrupted. The invention still further provides isolated 27960 proteins, fusion proteins, antigenic peptides and anti-27960 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: April 25, 2001
    Publication date: January 10, 2002
    Inventors: Rachel A. Meyers, Fong-Ying Tsai
  • Publication number: 20020001807
    Abstract: The invention provides isolated nucleic acids molecules, designated 21509 or 33770 nucleic acid molecules, which encode novel dehydrogenase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 21509 or 33770 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 21509 or 33770 gene has been introduced or disrupted. The invention still further provides isolated 21509 or 33770 proteins, fusion proteins, antigenic peptides and anti-21509 or 33770 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: March 30, 2001
    Publication date: January 3, 2002
    Inventors: Rachel A. Meyers, Laura A. Rudolph-Owen
  • Publication number: 20010044131
    Abstract: The present invention relates to a newly identified human PGP synthase. The invention also relates to polynucleotides encoding the PGP synthase. The invention further relates to methods using the PGP synthase polypeptides and polynucleotides as a target for diagnosis and treatment in PGP synthase-mediated or -related disorders. The invention further relates to drug-screening methods using the PGP synthase polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the PGP synthase polypeptides and polynucleotides. The invention further relates to procedures for producing the PGP synthase polypeptides and polynucleotides.
    Type: Application
    Filed: February 28, 2001
    Publication date: November 22, 2001
    Inventor: Rachel A. Meyers
  • Publication number: 20010039331
    Abstract: The invention provides isolated nucleic acids molecules, designated 16836 nucleic acid molecules, which encode novel phospholipase C members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 16836 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 16836 gene has been introduced or disrupted. The invention still further provides isolated 16836 proteins, fusion proteins, antigenic peptides and anti-16836 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: March 30, 2001
    Publication date: November 8, 2001
    Inventors: John J. Hunter, Rachel A. Meyers
  • Publication number: 20010036649
    Abstract: Novel cytidine deaminase-like polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length cytidine deaminase-like proteins, the invention further provides isolated cytidine deaminase-like fusion proteins, antigenic peptides, and anti-cytidine deaminase-like antibodies. The invention also provides cytidine deaminase-like nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an cytidine deaminase-like gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: March 9, 2001
    Publication date: November 1, 2001
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel A. Meyers, Laura A. Rudolph-Owen